Related references
Note: Only part of the references are listed.Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis
Boan Li et al.
FOOD & FUNCTION (2021)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
Guifang Du et al.
CELL DEATH & DISEASE (2020)
Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma
Ying-Qi Feng et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
Rongdang Fu et al.
MEDICAL ONCOLOGY (2020)
Holistic Prediction of the pKa in Diverse Solvents Based on a Machine-Learning Approach
Qi Yang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Neratinib decreases pro-survival responses of [sorafenib plus vorinostat] in pancreatic cancer
Laurence Booth et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib
Chunzhan Wang et al.
PHARMACOLOGICAL RESEARCH (2020)
What intervention regimen is most effective prevention for Portal venous system thrombosis after splenectomy in cirrhotics patients with Portal hypertension? Systematic review and network meta-analysis
Hongda Ding et al.
PHARMACOLOGICAL RESEARCH (2020)
miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway
Qing-Ping Shao et al.
ONCOTARGETS AND THERAPY (2020)
Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents
Ying-Qi Feng et al.
ONCOTARGETS AND THERAPY (2020)
A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway
Shu Wang et al.
CELL DEATH & DISEASE (2020)
DNA methyltransferase mediates the hypermethylation of the microRNA 34a promoter and enhances the resistance of patient-derived pancreatic cancer cells to molecular targeting agents
Yan Ma et al.
PHARMACOLOGICAL RESEARCH (2020)
FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis
Hua Yang et al.
CELL DEATH & DISEASE (2020)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
Xudong Gao et al.
ONCOTARGETS AND THERAPY (2019)
Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo
Ling Wei et al.
PHARMACOLOGICAL RESEARCH (2019)
miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib
Leisheng Wang et al.
ONCOTARGETS AND THERAPY (2019)
TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR
Ella Bhagyaraj et al.
CELL CYCLE (2019)
MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents
Bin Yang et al.
CELL DEATH & DISEASE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient-derived cell invasion via a novel in vivo tumor model
Huiwei Sun et al.
ANIMAL MODELS AND EXPERIMENTAL MEDICINE (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer
Christian Breunig et al.
MOLECULAR ONCOLOGY (2018)
A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma
Hui Xie et al.
ONCOTARGETS AND THERAPY (2018)
Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells
Yingshi Zhang et al.
CELL DEATH & DISEASE (2018)
A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells
Yanli Wang et al.
ONCOTARGETS AND THERAPY (2018)
Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor lα and induces DNA damage by sequestering ferrous iron
Feifei Li et al.
CELL DEATH & DISEASE (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14
Quanbo Ji et al.
CELL DEATH & DISEASE (2017)
WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects
Fang Guan et al.
ONCOTARGET (2017)
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu et al.
ACTA PHARMACOLOGICA SINICA (2017)
AKT inactivation causes persistent drug tolerance to EGFR inhibitors
Osamu Tetsu et al.
PHARMACOLOGICAL RESEARCH (2015)
The Global Burden of Liver Disease: The Major Impact of China
Fu-Sheng Wang et al.
HEPATOLOGY (2014)
FBI-1 Enhances ETS-1 Signaling Activity and Promotes Proliferation of Human Colorectal Carcinoma Cells
Min Zhu et al.
PLOS ONE (2014)
LINE-1 ORF-1p functions as a novel HGF/ETS-1 signaling pathway co-activator and promotes the growth of MDA-MB-231 cell
Qian Yang et al.
CELLULAR SIGNALLING (2013)
High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma
Yong-Ping Yang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Binding analyses between human PPAR gamma-LBD and ligands - Surface plasmon resonance biosensor assay correlating with circular dichroic spectroscopy determination and molecular docking
CY Yu et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2004)
Share Paper
